Artiva Biotherapeutics (ARTV) EBT Margin (2023 - 2024)

Artiva Biotherapeutics (ARTV) posted quarterly EBT Margin of 5514.74% for Q1 2024, down 1017.11% quarter-over-quarter from 493.66% in Q4 2023.

Artiva Biotherapeutics (ARTV) EBT Margin (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has reported EBT Margin for 2 consecutive years, with 5514.74% the latest figure, recorded in Q1 2024.

In Q1 2024, EBT Margin changed N/A year-over-year to 5514.74%; the TTM figure through Dec 2024 stood at 39402.39% (changed N/A YoY), while the FY2024 annual figure was 26045.02%, down 2595948.0% from the prior year.
EBT Margin fell to 5514.74% in Q1 2024 per ARTV's latest filing, from 493.66% in the prior quarter.
Across five years, EBT Margin topped out at 42.13% in Q3 2023 and bottomed at 5514.74% in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Artiva Biotherapeutics	451.28 Mn	451.28 Mn	-	-

Download Data